Armistice Capital’s Capricor Therapeutics CAPR Stock Holding History

Armistice Capital’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-268,630	Closed	-$322K	–	83
2020 Q1	$322K	Buy	+268,630	New	+$375K	0.02%	77

Other funds holding CAPR

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital's CAPR Position: Q2 2020 in Review

Armistice Capital sold out of Capricor Therapeutics (CAPR) in Q2 2020, closing a stake of 268,630 shares — an estimated $322K sold.

Armistice Capital first reported a position in CAPR in Q1 2020 and held it in 1 quarter. The position peaked at $322K in Q1 2020. 33 funds tracked by Wall St. Rank hold CAPR as of Q2 2020.

Armistice Capital reported no remaining Capricor Therapeutics position as of Q2 2020 after selling out during the quarter.
Armistice Capital sold 268,630 Capricor Therapeutics shares in Q2 2020, an estimated $322K.
Armistice Capital first reported a position in Capricor Therapeutics in Q1 2020 and held it in 1 quarter.
Armistice Capital's Capricor Therapeutics position peaked at $322K in Q1 2020.
33 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2020.

Based on Armistice Capital's 13F filing for Q2 2020, filed 14 Aug 2020.